Pharmacogenetics of etanercept: Role of TNF-α gene polymorphisms in improving its efficacy

Giuseppe Murdaca, Francesca Spanò, Miriam Contatore, Andrea Guastalla, Ottavia Magnani, Francesco Puppo

Research output: Contribution to journalArticle

26 Citations (Scopus)

Abstract

Introduction: During the last decade, many new biological immune modulators have entered the market as new therapeutic principles. Biologics, including TNF-α inhibitors, are the new frontier in the treatment of immune-mediated or inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ankylosing spondylitis, systemic sclerosis, disseminated granuloma annulare, psoriasis and/or psoriatic arthritis. TNF-α inhibitors have demonstrated efficacy and are well tolerated in large, randomized, controlled clinical trials. However, a substantial proportion of patients do not respond to these agents and potential adverse drug reactions may be associated with its use.Areas covered: Pharmacogenetics has the potential of increasing drug efficiency by identifying genetic factors responsible for lack of response or toxicities to TNF-α inhibitors. In this review, we analyze the influence of several polymorphisms upon the efficacy and safety of TNF-α inhibitors.Expert opinion: Several polymorphisms have been proven to influence the response to etanercept. Among them, single nucleotide polymorphisms (SNPs) -308 G/G, -857 C/T, +489 GG and GA, HLA-DRB1-encoding SE (allele ∗0404 and allele ∗0101) favor the response to etanercept, whereas SNP -308 A/A and TNFR1A AA decrease the response. Large clinical studies are needed to confirm the relevance of these associations in order to tailor treatment and to decrease unnecessary toxicity.

Original languageEnglish
Pages (from-to)1703-1710
Number of pages8
JournalExpert Opinion on Drug Metabolism and Toxicology
Volume10
Issue number12
DOIs
Publication statusPublished - Dec 1 2014

Fingerprint

Pharmacogenetics
Polymorphism
Genes
Single Nucleotide Polymorphism
Alleles
Granuloma Annulare
Toxicity
HLA-DRB1 Chains
Psoriatic Arthritis
Nucleotides
Systemic Scleroderma
Ankylosing Spondylitis
Expert Testimony
Drug-Related Side Effects and Adverse Reactions
Biological Products
Psoriasis
Crohn Disease
Systemic Lupus Erythematosus
Rheumatoid Arthritis
Therapeutics

Keywords

  • Etanercept
  • Immune-mediated diseases
  • TNF-α gene polymorphisms
  • TNF-α inhibitors

ASJC Scopus subject areas

  • Toxicology
  • Pharmacology
  • Medicine(all)

Cite this

Pharmacogenetics of etanercept : Role of TNF-α gene polymorphisms in improving its efficacy. / Murdaca, Giuseppe; Spanò, Francesca; Contatore, Miriam; Guastalla, Andrea; Magnani, Ottavia; Puppo, Francesco.

In: Expert Opinion on Drug Metabolism and Toxicology, Vol. 10, No. 12, 01.12.2014, p. 1703-1710.

Research output: Contribution to journalArticle

Murdaca, Giuseppe ; Spanò, Francesca ; Contatore, Miriam ; Guastalla, Andrea ; Magnani, Ottavia ; Puppo, Francesco. / Pharmacogenetics of etanercept : Role of TNF-α gene polymorphisms in improving its efficacy. In: Expert Opinion on Drug Metabolism and Toxicology. 2014 ; Vol. 10, No. 12. pp. 1703-1710.
@article{1904f0ab7e67443590cb840a1c49ae75,
title = "Pharmacogenetics of etanercept: Role of TNF-α gene polymorphisms in improving its efficacy",
abstract = "Introduction: During the last decade, many new biological immune modulators have entered the market as new therapeutic principles. Biologics, including TNF-α inhibitors, are the new frontier in the treatment of immune-mediated or inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ankylosing spondylitis, systemic sclerosis, disseminated granuloma annulare, psoriasis and/or psoriatic arthritis. TNF-α inhibitors have demonstrated efficacy and are well tolerated in large, randomized, controlled clinical trials. However, a substantial proportion of patients do not respond to these agents and potential adverse drug reactions may be associated with its use.Areas covered: Pharmacogenetics has the potential of increasing drug efficiency by identifying genetic factors responsible for lack of response or toxicities to TNF-α inhibitors. In this review, we analyze the influence of several polymorphisms upon the efficacy and safety of TNF-α inhibitors.Expert opinion: Several polymorphisms have been proven to influence the response to etanercept. Among them, single nucleotide polymorphisms (SNPs) -308 G/G, -857 C/T, +489 GG and GA, HLA-DRB1-encoding SE (allele ∗0404 and allele ∗0101) favor the response to etanercept, whereas SNP -308 A/A and TNFR1A AA decrease the response. Large clinical studies are needed to confirm the relevance of these associations in order to tailor treatment and to decrease unnecessary toxicity.",
keywords = "Etanercept, Immune-mediated diseases, TNF-α gene polymorphisms, TNF-α inhibitors",
author = "Giuseppe Murdaca and Francesca Span{\`o} and Miriam Contatore and Andrea Guastalla and Ottavia Magnani and Francesco Puppo",
year = "2014",
month = "12",
day = "1",
doi = "10.1517/17425255.2014.970165",
language = "English",
volume = "10",
pages = "1703--1710",
journal = "Expert Opinion on Drug Metabolism and Toxicology",
issn = "1742-5255",
publisher = "Taylor and Francis Ltd.",
number = "12",

}

TY - JOUR

T1 - Pharmacogenetics of etanercept

T2 - Role of TNF-α gene polymorphisms in improving its efficacy

AU - Murdaca, Giuseppe

AU - Spanò, Francesca

AU - Contatore, Miriam

AU - Guastalla, Andrea

AU - Magnani, Ottavia

AU - Puppo, Francesco

PY - 2014/12/1

Y1 - 2014/12/1

N2 - Introduction: During the last decade, many new biological immune modulators have entered the market as new therapeutic principles. Biologics, including TNF-α inhibitors, are the new frontier in the treatment of immune-mediated or inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ankylosing spondylitis, systemic sclerosis, disseminated granuloma annulare, psoriasis and/or psoriatic arthritis. TNF-α inhibitors have demonstrated efficacy and are well tolerated in large, randomized, controlled clinical trials. However, a substantial proportion of patients do not respond to these agents and potential adverse drug reactions may be associated with its use.Areas covered: Pharmacogenetics has the potential of increasing drug efficiency by identifying genetic factors responsible for lack of response or toxicities to TNF-α inhibitors. In this review, we analyze the influence of several polymorphisms upon the efficacy and safety of TNF-α inhibitors.Expert opinion: Several polymorphisms have been proven to influence the response to etanercept. Among them, single nucleotide polymorphisms (SNPs) -308 G/G, -857 C/T, +489 GG and GA, HLA-DRB1-encoding SE (allele ∗0404 and allele ∗0101) favor the response to etanercept, whereas SNP -308 A/A and TNFR1A AA decrease the response. Large clinical studies are needed to confirm the relevance of these associations in order to tailor treatment and to decrease unnecessary toxicity.

AB - Introduction: During the last decade, many new biological immune modulators have entered the market as new therapeutic principles. Biologics, including TNF-α inhibitors, are the new frontier in the treatment of immune-mediated or inflammatory diseases, such as rheumatoid arthritis, systemic lupus erythematosus, Crohn's disease, ankylosing spondylitis, systemic sclerosis, disseminated granuloma annulare, psoriasis and/or psoriatic arthritis. TNF-α inhibitors have demonstrated efficacy and are well tolerated in large, randomized, controlled clinical trials. However, a substantial proportion of patients do not respond to these agents and potential adverse drug reactions may be associated with its use.Areas covered: Pharmacogenetics has the potential of increasing drug efficiency by identifying genetic factors responsible for lack of response or toxicities to TNF-α inhibitors. In this review, we analyze the influence of several polymorphisms upon the efficacy and safety of TNF-α inhibitors.Expert opinion: Several polymorphisms have been proven to influence the response to etanercept. Among them, single nucleotide polymorphisms (SNPs) -308 G/G, -857 C/T, +489 GG and GA, HLA-DRB1-encoding SE (allele ∗0404 and allele ∗0101) favor the response to etanercept, whereas SNP -308 A/A and TNFR1A AA decrease the response. Large clinical studies are needed to confirm the relevance of these associations in order to tailor treatment and to decrease unnecessary toxicity.

KW - Etanercept

KW - Immune-mediated diseases

KW - TNF-α gene polymorphisms

KW - TNF-α inhibitors

UR - http://www.scopus.com/inward/record.url?scp=84911407518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84911407518&partnerID=8YFLogxK

U2 - 10.1517/17425255.2014.970165

DO - 10.1517/17425255.2014.970165

M3 - Article

C2 - 25300969

AN - SCOPUS:84911407518

VL - 10

SP - 1703

EP - 1710

JO - Expert Opinion on Drug Metabolism and Toxicology

JF - Expert Opinion on Drug Metabolism and Toxicology

SN - 1742-5255

IS - 12

ER -